Valuation: Autolus Therapeutics plc

Market Cap 62Cr 53Cr 50Cr 46Cr 86Cr 5.96TCr 87Cr 590.86Cr 229.75Cr 2.99TCr 233.85Cr 228.79Cr 9.91TCr P/E 2026 *
-2.91x
P/E 2027 * -3.43x
Enterprise Value 62Cr 53Cr 50Cr 46Cr 86Cr 5.96TCr 87Cr 590.86Cr 229.75Cr 2.99TCr 233.85Cr 228.79Cr 9.91TCr EV / Sales 2026 *
4.16x
EV / Sales 2027 * 3.24x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-2.90%
1 week+2.63%
Current month+57.05%
1 month+61.38%
3 months+37.65%
6 months+28.57%
Current year+17.59%
1 week 2.31
Extreme 2.31
2.58
1 month 1.41
Extreme 1.41
2.58
Current year 1.18
Extreme 1.175
2.58
1 year 1.18
Extreme 1.175
2.58
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap.
29/06/26 Free

Director

79,167 0.0477%
18/03/26 Other

Director

3,10,000 0.1866%
18/03/26 Other

General Counsel

7,80,818 0.4700%
Change 5-day change 1-year change 3-year change Capi.($)
-2.90%+2.63%+33.71%-28.66% 62Cr
-0.66%+2.80%+40.55%-0.33% 8.27TCr
-4.30%+115.47%+412.13%+23.29% 5.54TCr
+2.68%+10.02%-19.76%-34.08% 5.79TCr
+1.42%+1.61%-0.67%+34.08% 5.26TCr
+1.41%+2.67%+11.00%+173.14% 4.89TCr
+0.62%+4.29%+56.57%-16.88% 3.22TCr
+0.13%+3.63%+50.49%+99.25% 2.59TCr
+0.60%+3.57%+0.15%+196.15% 2.21TCr
+1.95%-0.90%+58.65%+107.95% 1.65TCr
Average +0.68%+16.24%+64.28%+55.39% 3.95TCr
Weighted average by Cap. +1.00%+21.97%+75.16%+44.78%

Financials

2026 *2027 *
Net sales 15Cr 13Cr 12Cr 11Cr 21Cr 1.43TCr 21Cr 142.1Cr 55Cr 720.17Cr 56Cr 55Cr 2.38TCr 19Cr 16Cr 15Cr 14Cr 27Cr 1.84TCr 27Cr 182.55Cr 71Cr 925.18Cr 72Cr 71Cr 3.06TCr
Net income -22Cr -19Cr -18Cr -16Cr -30Cr -2.1TCr -31Cr -207.62Cr -81Cr -1.05TCr -82Cr -80Cr -3.48TCr -19Cr -16Cr -15Cr -14Cr -26Cr -1.78TCr -26Cr -175.89Cr -68Cr -891.45Cr -70Cr -68Cr -2.95TCr
Net Debt - -
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
24/26/24 $2.340 -2.90% 12,22,526
21/26/21 $2.410 -2.03% 24,10,590
20/26/20 $2.460 -3.15% 32,54,202
19/26/19 $2.540 +10.92% 78,40,758
18/26/18 $2.290 +0.44% 33,63,410
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.340USD
Average target price
8.725USD
Spread / Average Target
+272.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock